Mass Tort & MDL Plaintiff Funding in California

California gives an injured plaintiff two years from the date of injury to file suit (Cal. Civ. Proc. Code §335.1). For a mass tort involving a latent-onset injury — a drug or chemical exposure where the connection to the product isn't immediately apparent — California's discovery rule delays accrual until the plaintiff discovers, or through reasonable diligence should have discovered, both the injury and its wrongful cause. California's Supreme Court applied this discovery rule directly to a mass tort drug case in Jolly v. Eli Lilly & Co., 44 Cal. 3d 1103 (1988) (a DES case), holding that a plaintiff who suspects wrongdoing must investigate but is not held to accrual before that suspicion reasonably arises. California has no general statute of repose for consumer products, so an older exposure does not by itself cut off a claim the way it can in a repose state.

California applies pure comparative fault to a mass tort sounding in strict products liability, consistent with Daly v. General Motors Corp., 20 Cal. 3d 725 (1978) — a plaintiff's own fault reduces recovery proportionally but never bars it outright, regardless of the fault percentage found. This matters in a mass tort context because bellwether and global-settlement valuations often incorporate an assumed comparative-fault or causation-strength discount across the plaintiff population rather than litigating fault claim-by-claim.

California imposes no general statutory cap on compensatory damages in a mass tort action; the $250,000 MICRA non-economic damages cap applies only to medical malpractice and has no application to a product-based or toxic-exposure mass tort.

Pre-judgment interest is generally unavailable on unliquidated personal-injury damages prior to verdict in an individual California case; in a mass tort resolved through a global settlement rather than trial, compensation is instead allocated through the settlement's own point or matrix system rather than a judgment carrying statutory interest.

A California mass tort plaintiff's case may be transferred to a federal MDL under 28 U.S.C. §1407 for coordinated pretrial proceedings if the underlying claim was filed in, or is removable to, federal court. Claims filed in California state court are frequently coordinated instead through California's Judicial Council Coordination Proceedings (JCCP) mechanism (Cal. Code Civ. Proc. §404 et seq.), which consolidates related cases filed in different California counties before a single coordination judge — California is one of the most active state-court venues for JCCP mass tort coordination in the country, including talc, opioid, wildfire, and pharmaceutical litigation.

California regulates consumer litigation funding under the California Consumer Legal Funding Act (AB 931), Cal. Bus. & Prof. Code §§ 6250–6256. No percentage or APR cap.

How does California's discovery rule work for a mass tort with a long latency period?

Under Jolly v. Eli Lilly, the two-year clock doesn't start until a plaintiff discovers, or reasonably should discover, both the injury and a suspicion of its wrongful cause — which for a drug, chemical, or device exposure with a long latency period can be years or decades after the actual exposure occurred.

For funding purposes, this means a California mass tort claim can be entirely timely even though the underlying exposure happened long ago, but it also means the discovery date itself — not the exposure date — is the fact that has to be pinned down and documented, since that date controls whether the claim is inside or outside the two-year window.

Why does it matter whether a California mass tort plaintiff is in the JCCP or a federal MDL?

A JCCP coordinates related California state-court cases before a single state judge, while an MDL transfer under 28 U.S.C. §1407 consolidates federal cases nationally for pretrial purposes only, before remand back to the original district for trial if the case doesn't settle — different tracks with different bellwether schedules, judges, and procedural rules that can move at different speeds even within the same overall mass tort.

A funding decision has to identify which track — or both, since parallel JCCP and MDL proceedings over the same underlying tort are common — actually governs a specific plaintiff's case, since the pace of bellwether trials and any developing global settlement framework in that specific proceeding is what drives the realistic timeline to payout, not the mass tort's overall national profile.

How does a common benefit fund assessment affect what a California mass tort plaintiff actually nets?

Most coordinated mass tort proceedings — JCCP and MDL alike — impose a common benefit fund holdback, a percentage deducted from each individual settlement to compensate the leadership counsel who developed the case's shared discovery, expert, and causation work.

This holdback, plus the plaintiff's own attorney's fee and costs, comes off the top of a matrix-based settlement award before the plaintiff receives net proceeds, which is why funding underwriting for a mass tort plaintiff has to model the expected net recovery under the specific proceeding's fee and holdback structure rather than the gross settlement-matrix value alone.